[1] Rajasekhar K,Thimmaiah G.Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease[J].RSC Adv,2018, 8(42):23780-23804.
[2] 闫超群, 张帅, 周平,等. 阿尔茨海默病相关概念研究进展[J].中华老年多器官疾病杂志,2018, 17(4):305-308.
[3] McKhann G, Drachman D, Folstein M,et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease[J].Neurology,1984, 34(7):939-944.
[4] Dubois B,Feldman HH,Jacova C,et al. Revising the definition of Alzheimer's disease: a new lexicon[J].Lancet Neurology,2010, 9(11):1118-1127.
[5] 5 Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J].Alzheimers Dement,2011, 7(3):257-262.
[6] Alzheimer's Association. Alzheimer's Association report: 2017 Alzheimer's disease facts and figures[J].Alzheimers Dement,2017, 13(4): 325-373.
[7] Petersen RC. Mild cognitive impairment as a diagnostic entity[J].J Int Med,2004, 256(3): 183-194.
[8] Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease[J].Alzheimers Dement,2014, 10(6):844-852.
[9] Huang YQ, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study[J].Lancet Psychiatry,2019,6(3):211-224.
[10] Zhao XX, Li XY. The prevalence of Alzheimer's disease in the Chinese Han population: a meta-analysis[J].Neurol Res,2020,42(4):291-298.
[11] Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later[J].Arch Neurol,2009, 66(12):1447-1455.
[12] Jia JP, Zhou AH, Wei CB, et al. The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese[J].Alzheimers Dement,2014, 10 (4): 439-447.
[13] Xue J, Li JR, Liang JM, et al.The Prevalence of mild cognitive impairment in China: a systematic review[J].Aging Dis,2018, 9(4):706-715.
[14] Tobiansky R, Blizard R, Livingston G, et al. The Gospel Oak Study Stage IV: the clinical relevance of subjective memory impairment in older people[J].Psychol Med,1995, 25(4):779-786.
[15] Hao LX, Wang XN, Zhang L, et al. Prevalence, risk factors, and complaints screening tool exploration of subjective cognitive decline in a large cohort of the Chinese population[J].J Alzheimers Dis,2017, 60(2): 371-388.
[16] Xiao SF, Lewis M, Mellor D, et al. The China longitudinal ageing study: overview of the demographic, psychosocial and cognitive data of the Shanghai sample[J].J Ment Health,2016,25(2):131-136.
[17] 周晓琴,陆健,莫晶, 等. 老年人主观记忆抱怨与客观认知损害的关联性[J].中国临床心理学杂志, 2019, 27(3):520-523.
[18] American Psychiatric Association(APA). Diagnostic and Statistical Manual, 5th Edition (DSM-5)[M].Washington, DC:American Psychiatric Publishing,2013.
[19] 中国痴呆与认知障碍指南写作组, 中国医师协会神经内科医师分会认知障碍疾病专业委员会. 2018中国痴呆与认知障碍诊治指南(一):痴呆及其分类诊断标准[J].中华医学杂志, 2018, 13:965-970.
[20] 田金洲, 时晶,张新卿, 等. 轻度认知损害临床研究指导原则(草案)编写说明[J].中西医结合学报, 2008, 6(1):15-21.
[21] Reisberg B , Prichep L , Mosconi L , et al. The pre–mild cognitive impairment, subjective cognitive impairment stage of Alzheimer's disease[J].Alzheimers Dement,2008, 4(1 suppl 1):S98-S108.
[22] Guzman-Martinez L, Maccioni R, Gonzalo Farías, et al. Biomarkers for Alzheimer's disease[J].Curr Alzheimer Res,2019, 16(6):518-528.
[23] Tanzi RE . The genetics of Alzheimer disease[J].Cold Spring Harbor Perspect Med,2012, 2(10):a006296.
[24] Lambert JC, Ibrahimverbaas CA, Harold D,et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease[J].Nat Genet,2013, 45(12):1452-1458.
[25] Ray S , Britschgi M , Herbert C , et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins[J].Nat Med,2007, 13(11):1359-1362.
[26] Long J, Pan G, Ifeachor E, et al. Discovery of novel biomarkers for Alzheimer's disease from blood[J].Dis Markers,2016, 2016:4250480.
[27] Cheng Z, Yin J, Yuan H, et al. Blood-derived plasma protein biomarkers for Alzheimer's disease in Han Chinese[J].Front Aging Neurosci,2018, 10:414.
[28] 李潭,张萌,林韬,等. 阿尔茨海默病治疗药物的研究现状[J].中国临床药理学杂志, 2019, 35(19): 2479-2482.
[29] Yiannopoulou KG, Papageorgiou SG. Current and future treatments in Alzheimer isease: an update[J].J Cent Nerv Syst Dis,2020, 12:1179573520907397.
[30] 杨宏伟,雷平,张明义. 药物治疗阿尔茨海默病的系统评价[J].解放军预防医学杂志, 2017, 35(5):523-526.
[31] Hampel H, Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease[J].Brain,2018, 141(7):1917-1933.
[32] Shinji M , Taro K , Nakao I , et al. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis[J].PLoS One,2015, 10(4):e0123289.
[33] Desai AK, Galliano Desai F. Management of behavioral and psychological symptoms of dementia[J].Curr Geriatry Rep,2019,21(8):66.
[34] Du XG, Wang XY, Geng MY. Alzheimer's disease hypothesis and related therapies[J].Transl Neurodegene,2018, 7:2.
[35] Cummings J, Lee G, Ritter A, et al. Alzheimer's disease drug development pipeline: 2019[J].Alzheimers Dement,2019, 5:272-293.
[36] Andrade S, Ramalho MJ, Loureiro JA,et al. Natural Compounds for Alzheimer's disease therapy: a systematic review of preclinical and clinical studies[J].Int J Mol Sci,2019, 20(9): 2313.
[37] XIAO SF. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer disease[J].中国药理学与毒理学杂志, 2019, 33(6): 403.
[38] 刘慧瑛, 夏兆云, 刘旺, 等. 基于阿尔茨海默病常见症状的非药物治疗[J].神经损伤与功能重建, 2020, 15(1):26-28.
2020, Vol. 37 
